glp-1 news As Drugs Go Mainstream, This Expert Says Health is More than a Number on a Scale Can one drug do it
Description
Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
It would take a leap of faith for a drug company to think there was something actually in this, Raufman said
GLP-1 [37]
This distinction matters not just to drug developers, but to the broader drug manufacturing market: as peptide drug volumes scale, demand surges for the reagents, instrumentation, contract manufacturing capacity, and analytical workflows that underpin both approaches
The primary outcome of this study was the first diagnosis of CRC within 15 years from the initial treatment of GLP-1RAs or non-GLP-1RA diabetes medications (insulin, metformin, alpha-glucosidase inhibitors, dipeptidyl-peptidase-4 inhibitors (DPP-4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i), sulfonylureas (SU), and thiazolidinediones (TZD))
